In the Phase IIIa FRONTIER 2 trial, participants aged 12 years and older administered Mim8 showed significant and superior reduction of treated bleeding episodes.
Results from FRONTIER 2 Trial Show Promise of Mim8 as a Potential Treatment for Hemophilia A